Will the price of Sotorasib rise in 2024?

Sotorasib is a new type of targeted anti-cancer drug specifically designed to treat KRAS G12C mutated non-small cell lung cancer (NSCLC). KRAS G12C mutation is a common gene mutation in various cancers, especially in NSCLC patients.

The original drug of sotorasibu has not yet been launched in China, so patients cannot purchase it domestically and need to purchase sotorasibu through overseas channels. The price of the original version of sotorasibu in Hong Kong, China, with the specifications of 120mg*240 tablets, is around 8 million, and the price of the European version of the original drug with the same specifications is around 4 million, which is relatively expensive. The cheaper ones are the generic drugs marketed abroad. For example, the price of generic drugs in Laos and Bangladesh is around two to three thousand yuan. The price is relatively cheap, and the ingredients of foreign generic drugs are basically the same as the original drugs.

Whether the price will increase depends on the specific situation, such as the pricing of pharmaceutical manufacturers and pharmacies, etc.

As aKRAS G12Cinhibitor, sotoraxib precisely targets this specific gene mutation and interferes with its activity, thereby inhibiting abnormal signaling pathways and hindering the growth and spread of cancer cells. This precision treatment strategy makes sotorasib an important treatment option for patients with KRAS G12C mutated non-small cell lung cancer.

Clinical trial data show that sotorasiib exhibits significant anti-tumor activity in some KRAS G12CmutantNSCLC patients who have previously had limited response to traditional treatments. Patients may experience tumor shrinkage or stabilization after treatment with sotoraxib, bringing new hope to patients with this specific subtype of lung cancer.

However, sotoracib is not suitable for allNSCLC patients, and its indication is limited to patients with KRAS G12C mutations. Before using sotoraxib, patients will need to undergo genetic testing to confirm their mutation status.